BRPI0615837A2 - método para a determinação quantitativa de poloxámeros - Google Patents

método para a determinação quantitativa de poloxámeros Download PDF

Info

Publication number: BRPI0615837A2
Authority: BR; Brazil
Prior art keywords: protein; poloxamer; fsh; sample; approximately
Prior art date: 2005-09-14

Application number

BRPI0615837-4A

Other languages

English (en)

Portuguese (pt)

Inventor

Mara Rossi

Original Assignee

Ares Trading Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-09-14

Filing date

2006-09-14

Publication date

2011-05-31

2006-09-14 Application filed by Ares Trading Sa filed Critical Ares Trading Sa

2006-09-14 Priority claimed from PCT/EP2006/066383 external-priority patent/WO2007031566A1/en

2011-05-31 Publication of BRPI0615837A2 publication Critical patent/BRPI0615837A2/pt

Links

229920001983 poloxamer Polymers 0.000 title claims abstract description 51
238000000034 method Methods 0.000 title claims description 41
102000004169 proteins and genes Human genes 0.000 claims abstract description 68
108090000623 proteins and genes Proteins 0.000 claims abstract description 68
239000007788 liquid Substances 0.000 claims abstract description 29
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 69
229960000502 poloxamer Drugs 0.000 claims description 34
229920001993 poloxamer 188 Polymers 0.000 claims description 30
229940044519 poloxamer 188 Drugs 0.000 claims description 30
108010051696 Growth Hormone Proteins 0.000 claims description 14
108090000467 Interferon-beta Proteins 0.000 claims description 14
239000000122 growth hormone Substances 0.000 claims description 14
238000001542 size-exclusion chromatography Methods 0.000 claims description 13
238000001514 detection method Methods 0.000 claims description 12
102000006771 Gonadotropins Human genes 0.000 claims description 8
108010086677 Gonadotropins Proteins 0.000 claims description 8
239000002622 gonadotropin Substances 0.000 claims description 8
239000000833 heterodimer Substances 0.000 claims description 7
239000008194 pharmaceutical composition Substances 0.000 claims description 7
102000003996 Interferon-beta Human genes 0.000 claims description 6
238000010828 elution Methods 0.000 claims description 6
239000002245 particle Substances 0.000 claims description 6
230000002378 acidificating effect Effects 0.000 claims description 5
238000004458 analytical method Methods 0.000 claims description 5
239000003125 aqueous solvent Substances 0.000 claims description 5
239000011159 matrix material Substances 0.000 claims description 5
239000011148 porous material Substances 0.000 claims description 5
239000011324 bead Substances 0.000 claims description 4
238000000926 separation method Methods 0.000 claims description 4
238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 claims description 4
230000007717 exclusion Effects 0.000 claims description 3
102100029223 Teashirt homolog 1 Human genes 0.000 claims description 2
101710201303 Threonine synthase-like 1 Proteins 0.000 claims description 2
229960001388 interferon-beta Drugs 0.000 claims description 2
102100038803 Somatotropin Human genes 0.000 claims 3
102000009151 Luteinizing Hormone Human genes 0.000 description 43
108010073521 Luteinizing Hormone Proteins 0.000 description 43
229940040129 luteinizing hormone Drugs 0.000 description 43
239000000203 mixture Substances 0.000 description 34
238000009472 formulation Methods 0.000 description 30
102000011022 Chorionic Gonadotropin Human genes 0.000 description 29
108010062540 Chorionic Gonadotropin Proteins 0.000 description 29
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
229940015047 chorionic gonadotropin Drugs 0.000 description 16
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
238000002347 injection Methods 0.000 description 15
239000007924 injection Substances 0.000 description 15
239000000243 solution Substances 0.000 description 15
102000011923 Thyrotropin Human genes 0.000 description 14
108010061174 Thyrotropin Proteins 0.000 description 14
RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 14
241000282414 Homo sapiens Species 0.000 description 13
-1 VlIIC factor Proteins 0.000 description 13
239000000872 buffer Substances 0.000 description 12
102000018997 Growth Hormone Human genes 0.000 description 11
229940084986 human chorionic gonadotropin Drugs 0.000 description 11
239000012669 liquid formulation Substances 0.000 description 11
239000007787 solid Substances 0.000 description 11
108010082302 Human Follicle Stimulating Hormone Proteins 0.000 description 10
102000003864 Human Follicle Stimulating Hormone Human genes 0.000 description 10
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 10
229910001868 water Inorganic materials 0.000 description 10
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
229940088597 hormone Drugs 0.000 description 9
239000005556 hormone Substances 0.000 description 9
239000004094 surface-active agent Substances 0.000 description 9
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 8
102100026720 Interferon beta Human genes 0.000 description 8
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 8
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
238000003860 storage Methods 0.000 description 8
102000003886 Glycoproteins Human genes 0.000 description 7
108090000288 Glycoproteins Proteins 0.000 description 7
239000008363 phosphate buffer Substances 0.000 description 7
239000008213 purified water Substances 0.000 description 7
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 6
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
150000001413 amino acids Chemical class 0.000 description 6
230000000694 effects Effects 0.000 description 6
239000003480 eluent Substances 0.000 description 6
HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 6
229960004452 methionine Drugs 0.000 description 6
229920000642 polymer Polymers 0.000 description 6
108090000765 processed proteins & peptides Proteins 0.000 description 6
150000003839 salts Chemical class 0.000 description 6
102000003977 fibroblast growth factor 18 Human genes 0.000 description 5
108090000370 fibroblast growth factor 18 Proteins 0.000 description 5
230000002209 hydrophobic effect Effects 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 4
108090000099 Neurotrophin-4 Proteins 0.000 description 4
102000004264 Osteopontin Human genes 0.000 description 4
108010081689 Osteopontin Proteins 0.000 description 4
229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
239000002253 acid Substances 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
230000003385 bacteriostatic effect Effects 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
239000006260 foam Substances 0.000 description 4
230000003325 follicular Effects 0.000 description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
238000007918 intramuscular administration Methods 0.000 description 4
238000002844 melting Methods 0.000 description 4
230000008018 melting Effects 0.000 description 4
239000003595 mist Substances 0.000 description 4
QWVGKYWNOKOFNN-UHFFFAOYSA-N o-cresol Chemical compound CC1=CC=CC=C1O QWVGKYWNOKOFNN-UHFFFAOYSA-N 0.000 description 4
IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 4
229920001451 polypropylene glycol Polymers 0.000 description 4
239000011591 potassium Substances 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
239000002904 solvent Substances 0.000 description 4
230000004936 stimulating effect Effects 0.000 description 4
230000000638 stimulation Effects 0.000 description 4
238000003756 stirring Methods 0.000 description 4
238000007920 subcutaneous administration Methods 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 3
108010063738 Interleukins Proteins 0.000 description 3
102000015696 Interleukins Human genes 0.000 description 3
FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 3
229930195722 L-methionine Natural products 0.000 description 3
102100029268 Neurotrophin-3 Human genes 0.000 description 3
229910019142 PO4 Inorganic materials 0.000 description 3
229920002021 Pluronic® F 77 Polymers 0.000 description 3
229920002025 Pluronic® F 88 Polymers 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
239000000022 bacteriostatic agent Substances 0.000 description 3
229920001400 block copolymer Polymers 0.000 description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
108010006578 follitropin alfa Proteins 0.000 description 3
230000013595 glycosylation Effects 0.000 description 3
238000006206 glycosylation reaction Methods 0.000 description 3
229940094892 gonadotropins Drugs 0.000 description 3
229930182817 methionine Natural products 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
230000016087 ovulation Effects 0.000 description 3
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 3
239000010452 phosphate Substances 0.000 description 3
235000011007 phosphoric acid Nutrition 0.000 description 3
150000003016 phosphoric acids Chemical class 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000003643 water by type Substances 0.000 description 3
102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
108010009575 CD55 Antigens Proteins 0.000 description 2
102000003951 Erythropoietin Human genes 0.000 description 2
108090000394 Erythropoietin Proteins 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
102000004877 Insulin Human genes 0.000 description 2
108090001061 Insulin Proteins 0.000 description 2
108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 2
102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
108010025020 Nerve Growth Factor Proteins 0.000 description 2
108090000742 Neurotrophin 3 Proteins 0.000 description 2
102000003683 Neurotrophin-4 Human genes 0.000 description 2
102100033857 Neurotrophin-4 Human genes 0.000 description 2
229920002023 Pluronic® F 87 Polymers 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
102000036693 Thrombopoietin Human genes 0.000 description 2
108010041111 Thrombopoietin Proteins 0.000 description 2
108010009583 Transforming Growth Factors Proteins 0.000 description 2
102000009618 Transforming Growth Factors Human genes 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
238000004220 aggregation Methods 0.000 description 2
229910000147 aluminium phosphate Inorganic materials 0.000 description 2
229960000686 benzalkonium chloride Drugs 0.000 description 2
235000019445 benzyl alcohol Nutrition 0.000 description 2
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
102000035824 beta Subunit Follicle Stimulating Hormone Human genes 0.000 description 2
108010081485 beta Subunit Follicle Stimulating Hormone Proteins 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
239000003114 blood coagulation factor Substances 0.000 description 2
229940112869 bone morphogenetic protein Drugs 0.000 description 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
229960002242 chlorocresol Drugs 0.000 description 2
230000001276 controlling effect Effects 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
238000010494 dissociation reaction Methods 0.000 description 2
230000005593 dissociations Effects 0.000 description 2
229940105423 erythropoietin Drugs 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
238000005227 gel permeation chromatography Methods 0.000 description 2
229940057854 gonal f Drugs 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
235000012907 honey Nutrition 0.000 description 2
208000000509 infertility Diseases 0.000 description 2
230000036512 infertility Effects 0.000 description 2
231100000535 infertility Toxicity 0.000 description 2
229940125396 insulin Drugs 0.000 description 2
230000003993 interaction Effects 0.000 description 2
229940047122 interleukins Drugs 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
238000012417 linear regression Methods 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
229910001414 potassium ion Inorganic materials 0.000 description 2
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000002335 preservative effect Effects 0.000 description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
238000010926 purge Methods 0.000 description 2
238000011002 quantification Methods 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
229940083542 sodium Drugs 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910001415 sodium ion Inorganic materials 0.000 description 2
239000007921 spray Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
229940033663 thimerosal Drugs 0.000 description 2
MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
208000030507 AIDS Diseases 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
108010059616 Activins Proteins 0.000 description 1
102000005606 Activins Human genes 0.000 description 1
108010005853 Anti-Mullerian Hormone Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
FYEHYMARPSSOBO-UHFFFAOYSA-N Aurin Chemical compound C1=CC(O)=CC=C1C(C=1C=CC(O)=CC=1)=C1C=CC(=O)C=C1 FYEHYMARPSSOBO-UHFFFAOYSA-N 0.000 description 1
102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
108010039209 Blood Coagulation Factors Proteins 0.000 description 1
102000015081 Blood Coagulation Factors Human genes 0.000 description 1
239000004135 Bone phosphate Substances 0.000 description 1
108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
102100031092 C-C motif chemokine 3 Human genes 0.000 description 1
101710155856 C-C motif chemokine 3 Proteins 0.000 description 1
102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
102000055006 Calcitonin Human genes 0.000 description 1
108060001064 Calcitonin Proteins 0.000 description 1
241001060848 Carapidae Species 0.000 description 1
101800005309 Carboxy-terminal peptide Proteins 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
108010055166 Chemokine CCL5 Proteins 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
102100022641 Coagulation factor IX Human genes 0.000 description 1
102100036486 Cobalamin binding intrinsic factor Human genes 0.000 description 1
101710123904 Cobalamin binding intrinsic factor Proteins 0.000 description 1
102000016911 Deoxyribonucleases Human genes 0.000 description 1
108010053770 Deoxyribonucleases Proteins 0.000 description 1
241000004297 Draba Species 0.000 description 1
108010076282 Factor IX Proteins 0.000 description 1
102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 1
102400000321 Glucagon Human genes 0.000 description 1
108060003199 Glucagon Proteins 0.000 description 1
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
206010056438 Growth hormone deficiency Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
108010000521 Human Growth Hormone Proteins 0.000 description 1
102000002265 Human Growth Hormone Human genes 0.000 description 1
239000000854 Human Growth Hormone Substances 0.000 description 1
102000003839 Human Proteins Human genes 0.000 description 1
108090000144 Human Proteins Proteins 0.000 description 1
206010058359 Hypogonadism Diseases 0.000 description 1
102000006992 Interferon-alpha Human genes 0.000 description 1
108010047761 Interferon-alpha Proteins 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
102000015336 Nerve Growth Factor Human genes 0.000 description 1
108090000095 Neurotrophin-6 Proteins 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 description 1
102000003982 Parathyroid hormone Human genes 0.000 description 1
108090000445 Parathyroid hormone Proteins 0.000 description 1
108010001014 Plasminogen Activators Proteins 0.000 description 1
102000001938 Plasminogen Activators Human genes 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
108010076181 Proinsulin Proteins 0.000 description 1
101800004937 Protein C Proteins 0.000 description 1
102000017975 Protein C Human genes 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108090000103 Relaxin Proteins 0.000 description 1
102000003743 Relaxin Human genes 0.000 description 1
101100227764 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) FSH1 gene Proteins 0.000 description 1
101800001700 Saposin-D Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
239000004288 Sodium dehydroacetate Substances 0.000 description 1
102000019197 Superoxide Dismutase Human genes 0.000 description 1
108010012715 Superoxide dismutase Proteins 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
108010000499 Thromboplastin Proteins 0.000 description 1
102000002262 Thromboplastin Human genes 0.000 description 1
239000005844 Thymol Substances 0.000 description 1
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
102100033571 Tissue-type plasminogen activator Human genes 0.000 description 1
102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
102000011117 Transforming Growth Factor beta2 Human genes 0.000 description 1
102400001320 Transforming growth factor alpha Human genes 0.000 description 1
101800004564 Transforming growth factor alpha Proteins 0.000 description 1
101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
101800000304 Transforming growth factor beta-2 Proteins 0.000 description 1
108090000097 Transforming growth factor beta-3 Proteins 0.000 description 1
102000056172 Transforming growth factor beta-3 Human genes 0.000 description 1
206010054094 Tumour necrosis Diseases 0.000 description 1
206010000210 abortion Diseases 0.000 description 1
231100000176 abortion Toxicity 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000488 activin Substances 0.000 description 1
239000000556 agonist Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
239000003708 ampul Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000001455 anti-clotting effect Effects 0.000 description 1
239000000868 anti-mullerian hormone Substances 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
238000013459 approach Methods 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
229940000201 avapro Drugs 0.000 description 1
206010003883 azoospermia Diseases 0.000 description 1
UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
229960001950 benzethonium chloride Drugs 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
108010006025 bovine growth hormone Proteins 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000008366 buffered solution Substances 0.000 description 1
229960004015 calcitonin Drugs 0.000 description 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000002144 chemical decomposition reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229960004681 choriogonadotropin alfa Drugs 0.000 description 1
229960004407 chorionic gonadotrophin Drugs 0.000 description 1
INDBQWVYFLTCFF-UHFFFAOYSA-L cobalt(2+);dithiocyanate Chemical compound [Co+2].[S-]C#N.[S-]C#N INDBQWVYFLTCFF-UHFFFAOYSA-L 0.000 description 1
238000004737 colorimetric analysis Methods 0.000 description 1
230000009918 complex formation Effects 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
238000007872 degassing Methods 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
108700001680 des-(1-3)- insulin-like growth factor 1 Proteins 0.000 description 1
238000011161 development Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
230000032692 embryo implantation Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
229960004222 factor ix Drugs 0.000 description 1
229940126864 fibroblast growth factor Drugs 0.000 description 1
229940028334 follicle stimulating hormone Drugs 0.000 description 1
239000012634 fragment Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
102000034356 gene-regulatory proteins Human genes 0.000 description 1
108091006104 gene-regulatory proteins Proteins 0.000 description 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
229960004666 glucagon Drugs 0.000 description 1
125000003827 glycol group Chemical group 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
108091008039 hormone receptors Proteins 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
229940051026 immunotoxin Drugs 0.000 description 1
239000002596 immunotoxin Substances 0.000 description 1
231100000608 immunotoxin Toxicity 0.000 description 1
230000002637 immunotoxin Effects 0.000 description 1
239000007943 implant Substances 0.000 description 1
230000006698 induction Effects 0.000 description 1
239000000893 inhibin Substances 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
102000028416 insulin-like growth factor binding Human genes 0.000 description 1
108091022911 insulin-like growth factor binding Proteins 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
YOSHYTLCDANDAN-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2NN=NN=2)C(CCCC)=NC21CCCC2 YOSHYTLCDANDAN-UHFFFAOYSA-N 0.000 description 1
238000002955 isolation Methods 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
150000002605 large molecules Chemical class 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
229960001855 mannitol Drugs 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
239000000178 monomer Substances 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
230000001452 natriuretic effect Effects 0.000 description 1
229940053128 nerve growth factor Drugs 0.000 description 1
229940072228 neurontin Drugs 0.000 description 1
239000003900 neurotrophic factor Substances 0.000 description 1
229940032018 neurotrophin 3 Drugs 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
208000008634 oligospermia Diseases 0.000 description 1
230000036616 oligospermia Effects 0.000 description 1
231100000528 oligospermia Toxicity 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
230000002138 osteoinductive effect Effects 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000003002 pH adjusting agent Substances 0.000 description 1
239000000199 parathyroid hormone Substances 0.000 description 1
229960001319 parathyroid hormone Drugs 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
229940085991 phosphate ion Drugs 0.000 description 1
229960004838 phosphoric acid Drugs 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
230000003169 placental effect Effects 0.000 description 1
229940127126 plasminogen activator Drugs 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229940068977 polysorbate 20 Drugs 0.000 description 1
230000008569 process Effects 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
108010087851 prorelaxin Proteins 0.000 description 1
230000004952 protein activity Effects 0.000 description 1
229960000856 protein c Drugs 0.000 description 1
KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
238000003751 purification from natural source Methods 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
229940117012 serostim Drugs 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000002002 slurry Substances 0.000 description 1
229940079839 sodium dehydroacetate Drugs 0.000 description 1
235000019259 sodium dehydroacetate Nutrition 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 1
230000021595 spermatogenesis Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
229940089453 sudafed Drugs 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
229960000790 thymol Drugs 0.000 description 1
108010042974 transforming growth factor beta4 Proteins 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
239000013598 vector Substances 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/34—Size-selective separation, e.g. size-exclusion chromatography; Gel filtration; Permeation
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
- B01J20/28002—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their physical properties
- B01J20/28004—Sorbent size or size distribution, e.g. particle size
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
- B01J20/28054—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their surface properties or porosity
- B01J20/28078—Pore diameter
- B01J20/28083—Pore diameter being in the range 2-50 nm, i.e. mesopores
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6866—Interferon
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/76—Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Cell Biology (AREA)
Food Science & Technology (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Organic Chemistry (AREA)
Biophysics (AREA)
Nanotechnology (AREA)
Reproductive Health (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Investigating Or Analysing Biological Materials (AREA)
Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Medicinal Preparation (AREA)
Analysing Materials By The Use Of Radiation (AREA)
Peptides Or Proteins (AREA)

BRPI0615837-4A 2005-09-14 2006-09-14 método para a determinação quantitativa de poloxámeros BRPI0615837A2 (pt)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
EP05108439.0		2005-09-14
EP05108439		2005-09-14
US71764205P	2005-09-16	2005-09-16
US60/717,642		2005-09-16
PCT/EP2006/066383 WO2007031566A1 (en)	2005-09-14	2006-09-14	Method for the quantitative determination of poloxamers

Publications (1)

Publication Number	Publication Date
BRPI0615837A2 true BRPI0615837A2 (pt)	2011-05-31

Family

ID=35696020

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0615837-4A BRPI0615837A2 (pt)	2005-09-14	2006-09-14	método para a determinação quantitativa de poloxámeros

Country Status (10)

Country	Link
JP (1)	JP4897814B2 (de)
CN (1)	CN101262918B (de)
AT (1)	ATE547161T1 (de)
BR (1)	BRPI0615837A2 (de)
DK (1)	DK1951395T3 (de)
ES (1)	ES2378686T3 (de)
PT (1)	PT1951395E (de)
SI (1)	SI1951395T1 (de)
UA (1)	UA95461C2 (de)
ZA (1)	ZA200800253B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101343040B1 (ko) *	2010-12-28	2013-12-18	주식회사 삼양바이오팜	정제된 폴록사머 및 그의 정제방법
EP2968391A1 (de)	2013-03-13	2016-01-20	Moderna Therapeutics, Inc.	Langlebige polynukleotidmoleküle
AU2016211950A1 (en) *	2015-01-29	2017-07-13	Ares Trading S.A.	Immunoassays for high positively charged proteins
CN113424057B (zh) *	2019-04-19	2024-04-05	海正生物制药有限公司	组合物中泊洛沙姆188的检测方法
CN111289652A (zh) *	2020-03-16	2020-06-16	康立泰药业有限公司	注射剂中泊洛沙姆188的检测方法
CN111830168B (zh) *	2020-07-23	2022-07-22	吉林医药学院	一种泊洛沙姆的lc-hr-ms/ms定量分析方法
AU2022399314A1 (en)	2021-12-01	2024-06-20	Chugai Seiyaku Kabushiki Kaisha	Method for preparing antibody-containing formulation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4402263B2 (ja) *	1999-06-21	2010-01-20	パナソニック株式会社	クロマトグラフィー定量測定装置
TWI272948B (en) *	2003-05-01	2007-02-11	Ares Trading Sa	HSA-free stabilized interferon liquid formulations
WO2004104025A1 (en) *	2003-05-21	2004-12-02	Ares Trading S.A.	Method of chromatographic analysis of a protein solution

2006
- 2006-09-14 PT PT06793534T patent/PT1951395E/pt unknown
- 2006-09-14 AT AT06793534T patent/ATE547161T1/de active
- 2006-09-14 ZA ZA200800253A patent/ZA200800253B/xx unknown
- 2006-09-14 DK DK06793534.6T patent/DK1951395T3/da active
- 2006-09-14 CN CN2006800330791A patent/CN101262918B/zh active Active
- 2006-09-14 ES ES06793534T patent/ES2378686T3/es active Active
- 2006-09-14 SI SI200631288T patent/SI1951395T1/sl unknown
- 2006-09-14 JP JP2008530539A patent/JP4897814B2/ja active Active
- 2006-09-14 BR BRPI0615837-4A patent/BRPI0615837A2/pt not_active IP Right Cessation
- 2006-09-14 UA UAA200804714A patent/UA95461C2/ru unknown

Also Published As

Publication number	Publication date
PT1951395E (pt)	2012-03-21
ES2378686T3 (es)	2012-04-17
DK1951395T3 (da)	2012-04-02
SI1951395T1 (sl)	2012-04-30
CN101262918A (zh)	2008-09-10
ZA200800253B (en)	2009-05-27
UA95461C2 (en)	2011-08-10
ATE547161T1 (de)	2012-03-15
JP4897814B2 (ja)	2012-03-14
CN101262918B (zh)	2011-03-23
JP2009508132A (ja)	2009-02-26

Legal Events

Date	Code	Title	Description
2014-07-15	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 8A ANUIDADE.
2014-11-25	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2271 DE 15/07/2014.

Publication	Publication Date	Title
CN113398250B (zh)	2024-02-23	液体促性腺激素药物制剂及用途
KR101105486B1 (ko)	2012-01-13	Ｆｓｈ 및 ｌｈ과 비이온성 계면활성제의 액상 약제학적 제제
CN102821782B (zh)	2015-07-15	促卵泡激素的液体配制品
BRPI0615837A2 (pt)	2011-05-31	método para a determinação quantitativa de poloxámeros
IL190139A (en)	2011-11-30	Method for the determination of poloxamers
JP4871124B2 (ja)	2012-02-08	凍結乾燥ｆｓｈ／ｌｈ製剤
ES2358330T3 (es)	2011-05-09	Formulaciones farmacéuticas de fsh y/o lh líquidas o liofilizadas junto con el tensioactivo no iónico poloxámero 188 y un agente bacteriostático.
HK1119614B (en)	2011-08-26	Method for the quantitative determination of poloxamers
RU2599031C1 (ru)	2016-10-10	Водная композиция рекомбинантного фолликулостимулирующего гормона человека (варианты)
RS51806B (sr)	2011-12-31	Formulacije paratiroidnog hormona i njihova upotreba